Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin versus treatment of physician's choice in previously treated advanced non-small cell lung cancer
ACTRN12612000100897Phase 3Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of eribulin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Overall survival. Started Sep 2011; status: active, not recruiting.
02
Drugs
eribulin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12612000100897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000100897.